Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting [Yahoo! Finance]
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth? [Yahoo! Finance]